Antibody drug conjugates (adc) that bind to 24p4c12 proteins

Abstract

Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

1 . A method for inhibiting growth of a cancer cell in a human subject, comprising:
 administering to the subject an effective amount of an antibody drug conjugate, wherein the conjugate comprises an antibody or antigen binding fragment thereof conjugated to monomethyl auristatin E (MMAE), and wherein the antibody or fragment thereof comprises a heavy chain variable region amino acid sequence of SEQ ID NO: 20, from residue 20 to 143, and a light chain variable region amino acid sequence of SEQ ID NO: 22, from residue 23 to 130.   
     
     
         2 . The method of  claim 1 , wherein the antibody or antigen binding fragment thereof comprises the heavy chain amino acid sequence of SEQ ID NO: 20, from residue 20 to 469 and the light chain amino acid sequence of SEQ ID NO: 22, from residue 23 to 236 
     
     
         3 . The method of  claim 1 , wherein the cancer cell is a prostate cancer cell. 
     
     
         4 . The method of  claim 1 , wherein the cancer cell is a gastric cancer cell. 
     
     
         5 . The method of  claim 1 , wherein the cancer cell is a pancreatic cancer cell. 
     
     
         6 . The method of  claim 1 , wherein the cancer is ovarian cancer. 
     
     
         7 . The method of  claim 1 , further comprising administering radiotherapy to the subject. 
     
     
         8 . The method of  claim 1 , further comprising administering a chemotherapeutic agent other than the conjugate to the subject. 
     
     
         9 . A method for inhibiting growth of a cancer cell in a human subject, comprising:
 administering to the subject an effective amount of an antibody drug conjugate, wherein the conjugate comprises an antibody or antigen binding fragment thereof conjugated to monomethyl auristatin E (MMAE), and wherein the antibody or fragment thereof comprises the variable heavy chain and variable light chain amino acid sequences of an antibody produced by the hybridoma deposited under American Type Culture Collection (ATCC) Accession No. PTA-8602.   
     
     
         10 . The method of  claim 9 , wherein the antibody or antigen binding fragment thereof comprises the amino acid sequences of the heavy chain and light chain of an antibody produced by a hybridoma deposited under A.T.C.C. Accession No.: PTA-8602. 
     
     
         11 . The method of  claim 9 , wherein the cancer cell is a prostate cancer cell. 
     
     
         12 . The method of  claim 9 , wherein the cancer cell is a gastric cancer cell. 
     
     
         13 . The method of  claim 9 , wherein the cancer cell is a pancreatic cancer cell. 
     
     
         14 . The method of  claim 9 , wherein the cancer cell is ovarian cancer cell. 
     
     
         15 . The method of  claim 9 , further comprising administering radiotherapy to the subject. 
     
     
         16 . The method of  claim 9 , further comprising administering a chemotherapeutic agent other than the conjugate to the subject.